arrow
M

Montserrat Rivero

instituto de investigación valdecilla
H指数:30
被引数:2,886

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Course and Predictors of Biologic Therapy, Hospitalisation and Surgery: A Five‐Year Prospective Study in Newly Diagnosed Inflammatory Bowel Disease

新诊断炎症性肠病患者生物制剂治疗、住院及手术的临床过程与预测因素:一项为期五年的前瞻性研究

2026-10-110
OAAI
Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

先前生物制剂作用机制对炎症性肠病中抗TNF疗效的影响:一项ENEIDA注册研究

2026-08-120
PREAI
Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU
2025-11-010
PRE
Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers

新诊断炎症性肠病患者的全面蛋白质组学分析:潜在生物标志物的鉴定

2025-10-010
PRE
Frequency and Effectiveness of Dose Escalation and De-Escalation of Biologic Therapy in Inflammatory Bowel Disease: The RAINBOW-IBD Study of ENEIDA

生物制剂治疗炎症性肠病中剂量递增和递减的频率与效果:ENEIDA中的RAINBOW-IBD研究

2025-08-080
PRE
Psychomotor Development in Infants Following Maternal Exposure to Biologics: Results From the DUMBO Registry
2025-06-130
OAAI
Influence of Familial Inflammatory Bowel Disease History on the Use of Immunosuppressants, Biological Agents and Surgery in Patients with Pediatric-Onset of the Disease in the Era of Biological Therapies. Results from the ENEIDA Registry

有家族炎症性肠病史对生物制剂治疗时代儿童起病炎症性肠病患者免疫抑制剂、生物制剂使用及手术的影响。ENEIDA注册研究的结果。

2025-05-120
OA
Real-world short and long-term effectiveness of risankizumab in refractory Crohn's disease: RISANCROHN study from the ENEIDA Registry
2025-01-220
PRE
Feasibility and safety of endoscopic submucosal dissection in inflammatory bowel disease (ESDEUR-IBD): an interim analysis of European retrospective study
2025-01-220
PRE
Predictors of biologics/JAKi use, surgeries, and hospitalisations in a newly diagnosed cohort of IBD patients: Long-term outcomes from the nationwide EpidemIBD study of GETECCU
2025-01-220
PRE
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence

克罗恩病中的回肠优势与肠道手术增加和生物治疗使用增加相关,但治疗持续性较低。

2024-11-142
PRE
Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA
2024-11-012
PRE
Clinical and molecular characterization of steatotic liver disease in the setting of immune-mediated inflammatory diseases
2024-10-010
OAAI
Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study
2024-09-172
OAAI
Need for therapeutic escalation in patients with refractory ulcerative proctitis: Results from the PROCU study of the ENEIDA registry
2024-06-282
PRE
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA project
2024-06-240
PRE
Trends in Targeted Therapy Usage in Inflammatory Bowel Disease: TRENDY Study of ENEIDA
2024-05-080
OAAI